Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study
Indiana University
Summary
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adults ≥18 years of age * Clinical diagnosis of T1D * GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week * Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study * Willing and able to provide informed consent Exclusion Criteria: * No exclusion criteria other than those not meeting inclusion criteria above
Locations (7)
- Hoag Memorial HospitalNewport Beach, California
- Emory UniversityAtlanta, Georgia
- Northwestern UniversityChicago, Illinois
- Maine Health Research InstitutePortland, Maine
- Harvard Medical SchoolBoston, Massachusetts
- Henry Ford HospitalDetroit, Michigan